<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101149</url>
  </required_header>
  <id_info>
    <org_study_id>262231</org_study_id>
    <nct_id>NCT04101149</nct_id>
  </id_info>
  <brief_title>Genetic Causes of Familial Hypercholesterolemia</brief_title>
  <official_title>Genetiska Orsaker Till familjär Hyperkolesterolemi- Mekanism, Prognos Och Individanpassad Behandling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Örebro County</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial hypercholesterolemia (FH) is a common disease. The genetic background to FH is not
      yet fully understood. In the present prospective cohort study we aim to study the association
      between different clinical characteristics, gene mutations and prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective observational cohort study of patients with high clinical suspicion of
      familial hypercholesterolemia (FH) we aim to study the association between different clinical
      characteristics, gene mutations and prognosis.

      The included patients will undergo physical examination and extended blood sampling. DNA will
      be extracted and used for both whole genome sequencing and investigation of both known- ,
      unknown- and suspected mutations associated with FH.

      The patients will be followed in for 15 years in the Swedish patients registry and the
      Swedish cause of death registry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 2045</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of mutations.</measure>
    <time_frame>2 years</time_frame>
    <description>The prevalence of known and newly discovered mutations associated with FH in the study population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognosis, composite endpoint.</measure>
    <time_frame>10 years</time_frame>
    <description>Time to death (cardiovascular and total), hospitalization due to acute myocardial infarction, unstable angina, heart failure or stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis, individual endpoint.</measure>
    <time_frame>10 years</time_frame>
    <description>Time to the individual endpoints: death (cardiovascular and total), hospitalization due to acute myocardial infarction, unstable angina, heart failure, stroke.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients with high clinical suspicion of familial hypercholesterolemia. No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for investigation of lipids, electrolytes, markers of inflammation and
      myocardial injury. Blood samples for extraction of DNA for genetic analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with suspected FH referred to the cardiac clinic at Orebro University hospital
        and their first grade relatives.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 8 years or older.

          2. Clinical suspicion of FH

          3. Dutch Lipid Clinic Network Score of at least four or a first grade relative with a
             genetic deviation that may be associated with FH.

        Exclusion Criteria:

        1) Age below 8 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna M Nordenskjöld, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örebro University, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna M Nordenskjöld, MD, PhD</last_name>
    <phone>+46 19 6021000</phone>
    <email>anna.nordenskjold@regionorebrolan.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Green, PhD</last_name>
    <phone>+46 19 6021000</phone>
    <email>anna.green@regionorebrolan.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Örebro University hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna M Nordenskjöld, MD, PhD</last_name>
      <phone>+46 19 6021000</phone>
      <email>anna.nordenskjold@regionorebrolan.se</email>
    </contact>
    <contact_backup>
      <last_name>Anna Green, PhD</last_name>
      <phone>+46 19 6021000</phone>
      <email>anna.green@regionorebrolan.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

